Article

Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis.

Programme PAC-CI, Abidjan, Côte d'Ivoire.
AIDS Research and Human Retroviruses (Impact Factor: 2.46). 11/2007; 23(11):1338-47. DOI: 10.1089/aid.2006.0308
Source: PubMed

ABSTRACT The incidence and determinants of severe morbidity recurrence in sub-Saharan African HIV-infected adults on antiretroviral therapy (ART) have never been reported. In a prospective cohort study of HIV-infected adults in Abidjan the association of severe morbidity occurrence and recurrence with follow-up CD4 counts and ART on/off status was analyzed by means of multivariate failure analysis for recurrent events (Prentice, Williams, and Peterson model). A total of 608 patients (median CD4 290/mm3 ) was followed off ART for 1824 person-years (PY). Of these 187 started HAART (median CD4 174/mm3 ) and were followed for 328 PY. The incidence of first, second, and third severe morbidity events was 40.6/100 PY, 68.4/100 PY, and 93.9/100 PY during the off-ART period, and 28.4/100 PY, 39.4/100 PY, and 37.6/100 PY during the on-ART period, respectively. The rates of recurrences were higher than the rates of first episodes for almost all diseases, even after stratifying by CD4 count and by ART on/off status. In multivariate analysis, the time-updated CD4 count was independently associated with increasing rates of morbidity first events and recurrences, after adjustment on other covariates (p > 10(4) ). By contrast, there was no association between the ART on/off status and the morbidity rates after adjustment for CD4 count (p = 0.37). Introducing ART led to a clear reduction in morbidity, mainly related to the ART-induced increase in CD4 count. In HIV-infected patients on ART, the incidence of severe morbidity varied with the past history of morbidity. The past history of morbidity should be taken into account when comparing HIV morbidity rates before and after ART initiation.

Download full-text

Full-text

Available from: Eugène Messou, Jun 28, 2015
1 Follower
 · 
157 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: L’objectif de cette étude est de décrire le profil clinicobiologique, thérapeutique et évolutif actuel des patients infectés par le VIH (PVVIH) de la file active du service des maladies infectieuses et tropicales (SMIT) afin d’améliorer leur prise en charge. Il s’agit d’une étude rétrospective descriptive sur les dossiers des PVVIH hospitalisés dans le SMIT du CHU de Treichville (Abidjan) de 2006 à 2007. En deux ans, 447 patients ont été inclus. Leur âge moyen était de 39 ans [18 et 86 ans] et le sex-ratio de 0,69. Sur les 447 patients, 35 % étaient sans profession et 67 % étaient naïfs de traitement antirétroviral (TARV). La durée du TARV était inférieure à six mois chez 59 % des patients traités. Le délai moyen de mise sous TARV était de sept semaines. Parmi les patients naïfs de TARV, 41,9 % ont été perdus de vue, 35,9 % en attente du TARV et 22,1 % étaient dans l’attente du bilan initial. Au début du TARV, 79,6 % des patients avaient un taux de CD4 inférieur à 200/mm3. Les causes d’hospitalisation classant dans le sida étaient dominées par la tuberculose (34,2 %), la toxoplasmose cérébrale (17,9 %) et la cryptococcose neuroméningée (8 %). Les principales causes d’hospitalisation non classant dans le sida étaient la pyélonéphrite (6,5 %), la pneumopathie bactérienne (5,4 %) et l’encéphalite infectieuse indéterminée (4,9 %). La létalité hospitalière était de 24,4 % dont 22,9 % due à la tuberculose, 20,2 % due à la toxoplasmose cérébrale, 18,3 % due à l’encéphalite infectieuse indéterminée et 13,7 % due à la cryptococcose neuroméningée. Le profil des PVVIH hospitalisés est caractérisé par une immunodépression profonde liée à un diagnostic tardif et une mortalité élevée liée aux infections opportunistes sévères et un TARV tardif.
    Bulletin de la Société de pathologie exotique 02/2012; 106(1). DOI:10.1007/s13149-012-0246-9
  • Source
    Chinese medical journal 01/2009; 121(24):2613-21. · 1.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: West African adults with warning signs of failure of antiretroviral treatment (ART) at 6 months were assessed for the probability and factors associated with success at 36 months. After 6 months on ART, patients were included if they had a bad immunologic response (BIR) (month 6 CD4 count < pre-ART CD4 count + 50/mm(3)), incomplete virologic suppression (IVS) (month 6 plasma HIV-1 RNA >300 copies/ml), or both (Dual). They were followed for 30 months after inclusion. CD4 counts and HIV-1 RNA were measured every 3 months. We estimated the probability of reaching immunovirologic success (CD4 count >350/mm(3) and plasma HIV-1 RNA <300 copies/ml) and looked for determinants using Cox analysis. A total of 208 adults were included. Among patients in the IVS and Dual groups, 23% and 38% had at least one genotypic resistance mutation at month 6. The 36-month cumulative probability of immunovirologic success was 0.84 in BIR, 0.81 in IVS, and 0.67 in Dual (p = 0.02). Adjusting for CD4 count, viral load, ART regimen, and morbidity, patients who had no genotypic resistance mutations at month 6 or a medication possession ratio (MPR) >90% between month 6 and month 36 had a likelihood of success 3.8 and 3.6 higher than other patients. The 36-month probability of success was 0.56 and 0.86 in patients with an MPR <90% and >90% and 0.59 and 0.84 in patients with and without resistance. After warning signs of failure at 6 months, a large proportion of patients reaches immunovirologic success before 36 months provided there is a high rate of adherence to medication and the absence of early resistance mutations.
    AIDS research and human retroviruses 08/2009; 25(8):783-93. DOI:10.1089/aid.2009.0018 · 2.46 Impact Factor